FDA-cleared profile

AiMIFY (1.x)

Subtle Medical, Inc. · MRI · FDA-cleared (510(k))

Authorized purpose: Enhance GBCA-enhanced brain MRI images to improve lesion and tissue contrast for radiologist review while preserving the original post-contrast image context.

Clinical role
Background post-processing image enhancement before radiologist review.
Images and patients
MRI · Brain
Key limitation
Keep in mind: Use is tied to standard approved GBCA dosage and supported acquisition protocols. The FDA packet reports increased vessel conspicuity and false-lesion risks, including cases with major diagnostic impact, so enhanced images require radiologist review and should not be treated as an autonomous diagnostic result.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Enhance GBCA-enhanced brain MRI images to improve lesion and tissue contrast for radiologist review while preserving the original post-contrast image context.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: T1 pre-contrast and standard-dose T1 post-contrast brain MRI acquired with a GBCA; listed protocols include gradient echo, 3D BRAVO, 3D MPRAGE, 2D T1 spin echo, and T1 FLAIR/inversion recovery at 0.3T, 1.5T, or 3.0T on GE, Philips, Siemens, or Hitachi systems.
  • Who uses it?Intended users: Radiologists in an imaging center, clinic, or hospital.
  • What does the software produce?Output: Enhanced DICOM MRI image with improved relative CNR, CEP, and LBR; compatible MDDS sends the result to PACS or another DICOM node for clinical review. The software has no GUI and runs in the background.
  • What is its most important limitation?Key limitation: Use is tied to standard approved GBCA dosage and supported acquisition protocols. The FDA packet reports increased vessel conspicuity and false-lesion risks, including cases with major diagnostic impact, so enhanced images require radiologist review and should not be treated as an autonomous diagnostic result.

Clinical takeaway. Clinical role: Enhance GBCA-enhanced brain MRI images to improve lesion and tissue contrast for radiologist review while preserving the original post-contrast image context.

Evidence takeaway. Evidence from the reviewed source record: FDA K240290 evaluated 95 T1 brain cases, including 57 with lesions, with three board-certified neuroradiologists. Quantitative improvement versus standard post-contrast images was reported for CNR, LBR, and CEP with p < 0.0001; qualitative lesion-visibility endpoints were significantly better and image quality/artifact impact was not worse, also p < 0.0001. Exploratory findings included vessel-conspicuity impact in 11.58% of AiMIFY cases versus 3.51% standard cases and major-impact false lesions in 14% of cases.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Enhance GBCA-enhanced brain MRI images to improve lesion and tissue contrast for radiologist review while preserving the original post-contrast image context.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Background post-processing image enhancement before radiologist review.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
T1 pre-contrast and standard-dose T1 post-contrast brain MRI acquired with a GBCA; listed protocols include gradient echo, 3D BRAVO, 3D MPRAGE, 2D T1 spin echo, and T1 FLAIR/inversion recovery at 0.3T, 1.5T, or 3.0T on GE, Philips, Siemens, or Hitachi systems.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Enhanced DICOM MRI image with improved relative CNR, CEP, and LBR; compatible MDDS sends the result to PACS or another DICOM node for clinical review. The software has no GUI and runs in the background.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Imaging center, clinic, or hospital.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Radiologists in an imaging center, clinic, or hospital.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Use is tied to standard approved GBCA dosage and supported acquisition protocols. The FDA packet reports increased vessel conspicuity and false-lesion risks, including cases with major diagnostic impact, so enhanced images require radiologist review and should not be treated as an autonomous diagnostic result.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA K240290 evaluated 95 T1 brain cases, including 57 with lesions, with three board-certified neuroradiologists. Quantitative improvement versus standard post-contrast images was reported for CNR, LBR, and CEP with p < 0.0001; qualitative lesion-visibility endpoints were significantly better and image quality/artifact impact was not worse, also p < 0.0001. Exploratory findings included vessel-conspicuity impact in 11.58% of AiMIFY cases versus 3.51% standard cases and major-impact false lesions in 14% of cases.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA K240290 evaluated 95 T1 brain cases, including 57 with lesions, with three board-certified neuroradiologists. Quantitative improvement versus standard post-contrast images was reported for CNR, LBR, and CEP with p < 0.0001; qualitative lesion-visibility endpoints were significantly better and image quality/artifact impact was not worse, also p < 0.0001. Exploratory findings included vessel-conspicuity impact in 11.58% of AiMIFY cases versus 3.51% standard cases and major-impact false lesions in 14% of cases.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

AiMIFY (1.x) regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K240290
  • Samplen=95
  • IndependenceIndependence not established

K240290

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K240290. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: T1 pre-contrast and standard-dose T1 post-contrast brain MRI acquired with a GBCA; listed protocols include gradient echo, 3D BRAVO, 3D MPRAGE, 2D T1 spin echo, and T1 FLAIR/inversion recovery at 0.3T, 1.5T, or 3.0T on GE, Philips, Siemens, or Hitachi systems.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K240290: AiMIFY (1.x)

  2. Routing

    Source context, not route validation: The device receives and returns DICOM images through a compatible MDDS; the enhanced image is sent to PACS or another DICOM node. The device itself does not directly interact with the MR scanner and is described as not networked.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K240290: AiMIFY (1.x)

  3. AI processing

    Source context, not route validation: The exact FDA package describes AiMIFY as a software package that operates on off-the-shelf hardware (same as its predicate), running in the background without a user interface, and usable within the facility's network or remotely depending on the compatible MDDS. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Software package that operates on off-the-shelf Same Characteristics hardware" … "Because the software runs in the background, it has no user interface.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K240290: AiMIFY (1.x)

  4. Returned objects

    Source context, not route validation: Enhanced DICOM MRI image with improved relative CNR, CEP, and LBR; compatible MDDS sends the result to PACS or another DICOM node for clinical review. The software has no GUI and runs in the background.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K240290: AiMIFY (1.x)

  5. Viewer/worklist/report

    Unresolved route: Enhanced DICOM MRI image with improved relative CNR, CEP, and LBR; compatible MDDS sends the result to PACS or another DICOM node for clinical review. The software has no GUI and runs in the background.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K240290: AiMIFY (1.x)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes AiMIFY as a software package that operates on off-the-shelf hardware (same as its predicate), running in the background without a user interface, and usable within the facility's network or remotely depending on the compatible MDDS. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Software package that operates on off-the-shelf Same Characteristics hardware" … "Because the software runs in the background, it has no user interface.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The device receives and returns DICOM images through a compatible MDDS; the enhanced image is sent to PACS or another DICOM node. The device itself does not directly interact with the MR scanner and is described as not networked.
  • Exact FDA submission
  • Checked 2026-09-08
Security
Subtle Medical's current compliance page lists an annual SOC 2 Type II + HIPAA security audit, and ISO 13485:2016 (valid until 2027-07-12) and ISO/IEC 42001:2023 (valid until 2028-07-17) certificates. The page gives no audit period or report scope, and the SOC 2 report was not read.
  • Vendor-wide
  • Checked 2026-10-25

Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Result destination

PACS is explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for AiMIFY (1.x); FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K240290
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-08-21
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
21Fields reviewed
10Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K240290 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K240290: AiMIFY (1.x)

    U.S. Food and Drug Administration - Published 2024-08-21 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. AiMIFY (1.x) model card (K240290)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K240290

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  8. Subtle Medical Compliance

    Subtle Medical, Inc. - Accessed 2026-10-25

    Scope: security

Research history

  1. K240290 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K261405

ANDI 2.2

Imeka Solutions, Inc.

Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.

Modality
MRI
Anatomy
Brain
Decision
2026-05-28
FDA-cleared K260032

Morph

BeauBrain Healthcare, Inc.

Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.

Modality
MRI
Anatomy
Brain
Decision
2026-05-13
FDA-cleared K253057

AI-Rad Companion Brain MR

Siemens Healthcare GmbH

Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.

Modality
MRI
Anatomy
Brain
Decision
2026-01-22
FDA-cleared K253489

Swoop® Portable MR Imaging® System

Hyperfine, Inc.

Authorized purpose: Swoop Portable MR Imaging System provides ultra-low-field point-of-care head MRI for all ages and includes deep-learning T1, T2, FLAIR, and DWI reconstruction.

Modality
MRI
Anatomy
Brain
Decision
2025-12-12

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history